الفهرس 
HCV in EgyptOnly 14 pages are availabe for public view
 |  | from | 183 |  |  |
| | | from | 183 | | |
Abstract
Background: Egypt has the highest hepatitis C virus (HCV) prevalence in the world. It was estimated that HCV prevalence among the 15–59 years age group to be 14.7%. Today, HCV infection and its complications are among the leading public health challenges in Egypt. About 5- 25 % of people with chronic hepatitis C develop cirrhosis, generally after 20 to 30 years of living with the virus, according to the CDC. Cirrhosis can eventually lead to end-stage liver disease and liver failure. About 2- 6 % of patients with HCV-related cirrhosis develop hepatocellular carcinoma (HCC). Treatment of infection with HCV has changed substantially in the last 3 years, with new therapies now reaching cure rates defined by sustained virologic response (SVR) higher than 95%. The introduction of polymerase inhibitors set a new standard. The first in this class, sofosbuvir has shown significant effectiveness when combined with ribavirin and interferon in patients with genotype 1 HCV. Sofosbuvir also can be combined with another protease inhibitors